NDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAPHCON-A is a fixed-dose ophthalmic combination of naphazoline hydrochloride (a decongestant) and pheniramine maleate (an antihistamine) formulated as eye drops. It is indicated for temporary relief of ocular itching and redness due to allergic conjunctivitis. The drug works by constricting blood vessels in the eye and blocking histamine-mediated allergic responses.
LOE Approaching
Product is in late-lifecycle stage with approaching loss of exclusivity; brand teams should focus on lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NAPHCON-A offers limited career growth opportunities due to its mature, LOE-approaching lifecycle and lack of active clinical programs. Roles are primarily defensive/maintenance-focused within commercial and sales functions rather than strategic or innovation-driven positions.
Brand ManagerField Sales Representative
Worked on NAPHCON-A at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.